MannKind (MNKD) News Today $6.01 0.00 (0.00%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period MannKind (NASDAQ:MNKD) Trading Down 3.1% - Should You Sell?January 19 at 4:44 AM | americanbankingnews.comMannKind (NASDAQ:MNKD) Shares Down 3.1% - Time to Sell?MannKind (NASDAQ:MNKD) Trading Down 3.1% - Should You Sell?January 17 at 1:14 PM | marketbeat.comShort Interest in MannKind Co. (NASDAQ:MNKD) Drops By 30.4%MannKind Co. (NASDAQ:MNKD - Get Free Report) was the recipient of a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 28,800,000 shares, a decline of 30.4% from the December 15th total of 41,360,000 shares. Approximately 10.8% of the company's shares are sold short. Based on an average daily trading volume, of 2,670,000 shares, the short-interest ratio is presently 10.8 days.January 15, 2025 | marketbeat.comMannKind (MNKD) Receives a Buy from RBC CapitalJanuary 10, 2025 | markets.businessinsider.comMannKind Announces Upcoming Retirement of Lauren SabellaJanuary 7, 2025 | msn.comMannKind Expands Executive Leadership TeamJanuary 6, 2025 | globenewswire.comPrincipal Financial Group Inc. Boosts Holdings in MannKind Co. (NASDAQ:MNKD)Principal Financial Group Inc. boosted its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 401.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 168,518 shares of the biopharmaceutical company's stock after purchasing an additional 134January 5, 2025 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Receives Consensus Recommendation of "Buy" from BrokeragesMannKind Co. (NASDAQ:MNKD - Get Free Report) has earned an average recommendation of "Buy" from the nine brokerages that are covering the firm, MarketBeat.com reports. Eight research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the cDecember 31, 2024 | marketbeat.comMannKind (NASDAQ:MNKD) Shares Down 3.1% - Here's What HappenedMannKind (NASDAQ:MNKD) Shares Down 3.1% - Here's WhyDecember 24, 2024 | marketbeat.comInvestors Purchase High Volume of MannKind Call Options (NASDAQ:MNKD)MannKind Co. (NASDAQ:MNKD - Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Traders acquired 3,498 call options on the company. This represents an increase of 92% compared to the typical daily volume of 1,818 call options.December 24, 2024 | marketbeat.comBarclays PLC Buys 338,121 Shares of MannKind Co. (NASDAQ:MNKD)Barclays PLC grew its holdings in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 186.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 519,865 shares of the biopharmaceutical companDecember 24, 2024 | marketbeat.comFY2025 EPS Estimates for MannKind Cut by Leerink PartnrsMannKind Co. (NASDAQ:MNKD - Free Report) - Equities researchers at Leerink Partnrs cut their FY2025 earnings estimates for shares of MannKind in a research note issued to investors on Wednesday, December 18th. Leerink Partnrs analyst F. Khurshid now anticipates that the biopharmaceutical companyDecember 23, 2024 | marketbeat.comWells Fargo Initiates Coverage of MannKind (MNKD) with Overweight RecommendationDecember 21, 2024 | msn.comMannKind initiated with an Overweight at Wells FargoDecember 20, 2024 | markets.businessinsider.comLeerink Partners Sticks to Its Buy Rating for MannKind (MNKD)December 20, 2024 | markets.businessinsider.comMannKind stock up 10% amid bullish Wells Fargo noteDecember 20, 2024 | msn.comMannKind (NASDAQ:MNKD) pulls back 3.8% this week, but still delivers shareholders fantastic 36% CAGR over 5 yearsDecember 20, 2024 | finance.yahoo.comMannKind (NASDAQ:MNKD) Coverage Initiated by Analysts at Wells Fargo & CompanyWells Fargo & Company started coverage on shares of MannKind in a research note on Friday. They set an "overweight" rating and a $9.00 target price on the stock.December 20, 2024 | marketbeat.comLeerink Partnrs Lowers Earnings Estimates for MannKindMannKind Co. (NASDAQ:MNKD - Free Report) - Research analysts at Leerink Partnrs cut their FY2026 EPS estimates for MannKind in a note issued to investors on Wednesday, December 18th. Leerink Partnrs analyst F. Khurshid now forecasts that the biopharmaceutical company will post earnings per shareDecember 20, 2024 | marketbeat.comRBC Capital Upgrades MannKind (MNKD)December 20, 2024 | msn.comRBC upgrades MannKind on royalty revenue, orphan lung pipelineDecember 19, 2024 | markets.businessinsider.comMannKind upgraded to Outperform from Sector Perform at RBC CapitalDecember 19, 2024 | msn.comMannKind (NASDAQ:MNKD) Trading Up 5.7% - Here's WhyMannKind (NASDAQ:MNKD) Trading 5.7% Higher - Time to Buy?December 19, 2024 | marketbeat.comMannKind (NASDAQ:MNKD) Upgraded to Outperform at Royal Bank of CanadaRoyal Bank of Canada upgraded MannKind from a "sector perform" rating to an "outperform" rating and raised their price target for the stock from $7.00 to $10.00 in a research report on Thursday.December 19, 2024 | marketbeat.comMannKind Corporation Announces Exchange of Convertible Notes for Stock and CashDecember 18, 2024 | finance.yahoo.comLeerink Partners Keeps Their Buy Rating on MannKind (MNKD)December 18, 2024 | markets.businessinsider.comMannKind announces exchange of convertible notes for stock, cashDecember 18, 2024 | markets.businessinsider.comMannKind (NASDAQ:MNKD) Shares Gap Up - Still a Buy?MannKind (NASDAQ:MNKD) Shares Gap Up - Here's What HappenedDecember 18, 2024 | marketbeat.comMannKind to reduce debt by 84%December 18, 2024 | seekingalpha.comMannKind Co. (NASDAQ:MNKD) Shares Purchased by HighTower Advisors LLCHighTower Advisors LLC boosted its stake in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 300.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 143,393 shares of the biopharmaceutical company's stock after buyDecember 18, 2024 | marketbeat.comMannKind (NASDAQ:MNKD) Stock Price Down 5.4% - Here's WhyMannKind (NASDAQ:MNKD) Stock Price Down 5.4% - Here's What HappenedDecember 17, 2024 | marketbeat.comMannKind Corporation: A Speculative Buy On IPF And Diabetes MarketsDecember 17, 2024 | seekingalpha.comWellington Management Group LLP Increases Stake in MannKind Co. (NASDAQ:MNKD)Wellington Management Group LLP boosted its stake in MannKind Co. (NASDAQ:MNKD - Free Report) by 11.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 865,295 shares of the biopharmaceutical company's stock after buying aDecember 17, 2024 | marketbeat.comMannKind Shares Are falling Today: What's Going On?December 16, 2024 | benzinga.comMannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)December 16, 2024 | markets.businessinsider.comMannKind Reports Encouraging 6-month Data From Phase 3 INHALE-1 StudyDecember 16, 2024 | markets.businessinsider.comMannKind Corp (MNKD) Announces Promising Phase 3 Results for Afrezza in Pediatric Diabetes TreatmentDecember 16, 2024 | gurufocus.comMannKind reports six-month results from Phase 3 INHALE-1 trialDecember 16, 2024 | tipranks.comMannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)December 16, 2024 | globenewswire.comMannKind, Cipla: CDSCO in India approves Afrezza Inhalation Powder in IndiaDecember 11, 2024 | markets.businessinsider.comMannKind Stock Gains After India Approves Inhaled Insulin: Retail Excitement BuildsDecember 11, 2024 | msn.comMannKind Corp (MNKD) Gains Approval for Afrezza in IndiaDecember 11, 2024 | gurufocus.comCDSCO Approves Afrezza® (insulin human) Inhalation Powder in IndiaDecember 11, 2024 | globenewswire.comTwo Sigma Advisers LP Buys 1,000,600 Shares of MannKind Co. (NASDAQ:MNKD)Two Sigma Advisers LP increased its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 60.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,648,327 shares of the biopharmaceutical company's stock after aDecember 9, 2024 | marketbeat.comMannKind (NASDAQ:MNKD) Downgraded by StockNews.com to HoldStockNews.com cut MannKind from a "buy" rating to a "hold" rating in a report on Saturday.December 7, 2024 | marketbeat.comBNP Paribas Financial Markets Acquires 381,298 Shares of MannKind Co. (NASDAQ:MNKD)BNP Paribas Financial Markets lifted its holdings in MannKind Co. (NASDAQ:MNKD - Free Report) by 421.3% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 471,802 shares of the biopharmaceutical company's stock after acquiring an additional 381,298December 6, 2024 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Receives Average Recommendation of "Buy" from AnalystsMannKind Co. (NASDAQ:MNKD - Get Free Report) has been given a consensus recommendation of "Buy" by the seven brokerages that are currently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The averageDecember 6, 2024 | marketbeat.com1,947,813 Shares in MannKind Co. (NASDAQ:MNKD) Purchased by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. bought a new stake in shares of MannKind Co. (NASDAQ:MNKD - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 1,947,813 shares of the biopharmaceutical company's sDecember 5, 2024 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Shares Purchased by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC boosted its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 37.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,304,085 shares of the biopharmaceutical companyDecember 4, 2024 | marketbeat.comMannKind (NASDAQ:MNKD) Stock Rating Upgraded by StockNews.comStockNews.com upgraded MannKind from a "hold" rating to a "buy" rating in a report on Friday.November 29, 2024 | marketbeat.com Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address MNKD Media Mentions By Week MNKD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNKD News Sentiment▼0.400.44▲Average Medical News Sentiment MNKD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNKD Articles This Week▼34▲MNKD Articles Average Week Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Madrigal Pharmaceuticals News Ionis Pharmaceuticals News Alkermes News Amicus Therapeutics News Ligand Pharmaceuticals News Geron News Dynavax Technologies News Celldex Therapeutics News BioCryst Pharmaceuticals News Novavax News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNKD) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNKD Stock Alerts